EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study

Arishabhas Tantibhadrasapa, Songbo Li, Songphon Buddhasiri, Chutikarn Sukjoi, Panupon Mongkolkarvin, Pattarapon Boonpan, Somsakul Pop Wongpalee, Prasobsook Paenkaew, Sawannee Sutheeworapong, Massalin Nakphaichit, Sunee Nitisinprasert, Michael H Hsieh und 1 weitere

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1401462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Arishabhas Tantibhadrasapa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Probiotics, Uropathogenic Escherichia coli, Limosilactobacillus reuteri, Macrophages. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bacterial urinary tract infections (UTI) are among the most common infectious diseases worldwide. The rise of multidrug-resistant (MDR) uropathogenic Escherichia coli (UPEC) UTI cases is a significant threat to healthcare systems. Several probiotic bacteria have been proposed as an alternative to combat MDR UTI. Lactic acid bacteria in the genus Limosilactobacillus are some of the most studied and used probiotics. However, strain-specific effects play a critical role in probiotic properties. L. reuteri KUB-AC5 (AC5), isolated from the chicken gut, confers antimicrobial and immunobiotic effects against some human pathogens. However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.

Methods

Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro . Using a spot-on lawn, agar-well diffusion, and competitive growth assays, we found that viable AC5 cells and cell-free components of this probiotic significantly reduced the UPEC growth of all strains tested. The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC. Results and discussion Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. Pretreatment of UPEC-infected murine macrophage RAW264.7 cells with viable AC5 (multiplicity of infection, MOI = 1) for 24 hours enhanced macrophage-killing activity and increased proinflammatory ( Nos2 , Il6 , and Tnfa ) and anti-inflammatory ( Il10 ) gene expression. These findings indicate the gut-derived AC5 probiotic could be a potential urogenital probiotic against MDR UTI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsUropathogenic Escherichia coliLimosilactobacillus reuteriMacrophagesAnimalsMiceHumansUrotheliumUrinary Tract InfectionsCell LineEscherichia coli InfectionsRAW 264.7 CellsEpithelial CellsChickensBacterial Adhesion

Stichwörter der Autor:innen

Limosilactobacillus reuteriimmune modulationimmunobioticprobioticurinary tract infection (UTI)uropathogenic E. coli (UPEC)

Autor:innen und Institutionen

  • Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Key Laboratory of Tumor Immunopathology, Youjiang Medical University for Nationalities, Baise, China.
  • Research Center for Veterinary Biosciences and Veterinary Public Health, Chiang Mai University, Chiang Mai, Thailand.
  • Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Pilot Plant Development and Training Institute (PDTI), King Mongkut's University of Technology Thonburi (KMUTT), Bangkok, Thailand.
  • Department of Biotechnology, Faculty of Agro-Industry, Kasetsart University, Bangkok, Thailand.

Zitieren

APA

Tantibhadrasapa, A., Li, S., Buddhasiri, S., Sukjoi, C., Mongkolkarvin, P., Boonpan, P., Wongpalee, S. P., Paenkaew, P., Sutheeworapong, S., Nakphaichit, M., Nitisinprasert, S., Hsieh, M. H., & Thiennimitr, P. (2024). Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1401462

Vancouver

Tantibhadrasapa A, Li S, Buddhasiri S, Sukjoi C, Mongkolkarvin P, Boonpan P, et al. Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1401462

BibTeX
@article{Tantibhadrasapa2024,
  author = {Tantibhadrasapa, Arishabhas and Li, Songbo and Buddhasiri, Songphon and Sukjoi, Chutikarn and Mongkolkarvin, Panupon and Boonpan, Pattarapon and Wongpalee, Somsakul Pop and Paenkaew, Prasobsook and Sutheeworapong, Sawannee and Nakphaichit, Massalin and Nitisinprasert, Sunee and Hsieh, Michael H and Thiennimitr, Parameth},
  title = {Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1401462}
}
Kostenlos starten →